Market Indices
Sector Heatmap
INCY — Incyte Genomics Inc
NasdaqIncyte Genomics Inc
- O
- 116.76
- H
- 117.19
- L
- 114.57
- V
- 2.16M
INCY — Latest News & Headlines
20 StoriesIncyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Yahoo Finance
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data Yahoo Finance
Incyte (INCY) Stock Could Be 33% Overvalued After Fresh EADV Data - Simply Wall Street
Incyte (INCY) Stock Could Be 33% Overvalued After Fresh EADV Data Simply Wall Street
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte Stock Price Forecast. Should You Buy INCY? StockInvest.us
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
A legal chief with more than 25 years in pharma and biotech joins MiniMed. Stock Titan
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today - Benzinga
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today Benzinga
INCY Maintained by HC Wainwright & Co. -- Price Target Raised to $152 - gurufocus.com
INCY Maintained by HC Wainwright & Co. -- Price Target Raised to $152 gurufocus.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? Yahoo Finance
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna Stock Titan
INCY Maintained by JP Morgan -- Price Target Raised to $123.00 - gurufocus.com
INCY Maintained by JP Morgan -- Price Target Raised to $123.00 gurufocus.com
INCY or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
INCY or TECH: Which Is the Better Value Stock Right Now? Yahoo Finance
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. - Stock Titan
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. Stock Titan
Learn Why The Bull Case For Incyte (INCY) Could Change Following Rare Disease Drug Approval - Simply Wall Street
Learn Why The Bull Case For Incyte (INCY) Could Change Following Rare Disease Drug Approval Simply Wall Street
A $40,500 director retainer becomes 322 shares for Julian C. Baker at Incyte (INCY). - Stock Titan
A $40,500 director retainer becomes 322 shares for Julian C. Baker at Incyte (INCY). Stock Titan
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill - Yahoo Finance
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill Yahoo Finance
203 shares replace director fees at Incyte (INCY), with the award fully vested. - Stock Titan
203 shares replace director fees at Incyte (INCY), with the award fully vested. Stock Titan
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data Yahoo Finance
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. Stock Titan
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment Yahoo Finance
Shares replace quarterly director fees as Incyte (INCY) awards 206 fully vested shares. - Stock Titan
Shares replace quarterly director fees as Incyte (INCY) awards 206 fully vested shares. Stock Titan
Incyte (INCY), What Is Behind The Fresh Attention? - Simply Wall Street
Incyte (INCY), What Is Behind The Fresh Attention? Simply Wall Street